[Nicorandil: Acute Hemodynamic Effects of 2 Different Oral Doses of a Potassium Channel Opener in Patients with Coronary Heart Disease]

Overview

Journal Med Klin (Munich)

Specialty General Medicine

Date 1999 Apr 9

PMID 10194949

Authors

C Bickel

H J Rupprecht

A Tyrtania

J Rorig

J Meyer

Affiliations

Soon will be listed here.

Abstract

Background: In medical treatment of angina pectoris the 3 major groups of antianginal agents are nitrates, beta blockers and calcium antagonists. Now a new class of drugs is introduced in the therapy: the potassium channel openers. One of the first potassium channel openers is nicorandil. We examined the acute hemodynamic effects of 2 different oral nicorandil doses in patients with coronary heart disease.

Patients And Methods: Twenty patients with angiographic proven coronary heart disease and stable angina pectoris were treated with a dose of 2 x 10 mg Nicorandil on day 1 and 2 x 20 mg Nicorandil on day 2, while being hemodynamically monitored on an intensive care unit with a pulmonary artery catheter.

Results: Through the hemodynamic monitoring a dose dependent, significant reduction of systolic blood pressure was found (6%/9%), while the heart rate increased dose dependently (6%/11%). The rate pressure product as a marker of myocardial oxygen demand did not increase significantly.

Conclusion: The oral application of nicorandil causes an acute, dose dependent, significant decrease in systolic blood pressure and induces a reflextachycardia.

References

Ghaleh B, Dubois-Rande J, Hittinger L, Giudicelli J, Berdeaux A . Comparisons of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium. Br J Pharmacol. 1995; 114(2):496-502. PMC: 1510239. DOI: 10.1111/j.1476-5381.1995.tb13254.x. View

Ulvenstam G, Diderholm E, Frithz G, Gudbrandsson T, Hedback B, Hoglund C . Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol. 1992; 20 Suppl 3:S67-73. DOI: 10.1097/00005344-199206203-00012. View

Krumenacker M, Roland E . Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol. 1992; 20 Suppl 3:S93-102. View

Wolf D, Hearron A, Metzler C, FERRY J, Froeschke M, Luderer J . The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers. Eur J Clin Pharmacol. 1993; 45(5):437-43. DOI: 10.1007/BF00315515. View

Kool M, Spek J, Struyker Boudier H, Hoeks A, Reneman R, van Herwaarden R . Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers. Cardiovasc Drugs Ther. 1995; 9(2):331-7. DOI: 10.1007/BF00878678. View

Knight C, Purcell H, Fox K . Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther. 1995; 9 Suppl 2:229-36. DOI: 10.1007/BF00878470. View

Ogawa N, Fukata Y, KANETA S, Jinno Y, Fukushima H, Nishikori K . Comparison of KRN2391 with nicorandil and nifedipine on canine coronary blood flow: antagonism by glibenclamide. J Cardiovasc Pharmacol. 1992; 20(1):11-7. View

Kukovetz W, Holzmann S, Poch G . Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol. 1992; 20 Suppl 3:S1-7. DOI: 10.1097/00005344-199206203-00002. View

Kukovetz W, Holzmann S, Braida C, Poch G . Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization. J Cardiovasc Pharmacol. 1991; 17(4):627-33. DOI: 10.1097/00005344-199104000-00016. View

10.

Guermonprez J, Blin P, Peterlongo F . A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J. 1993; 14 Suppl B:30-4. DOI: 10.1093/eurheartj/14.suppl_b.30. View

11.

Treese N, Erbel R, Meyer J . Acute hemodynamic effects of nicorandil in coronary artery disease. J Cardiovasc Pharmacol. 1992; 20 Suppl 3:S52-6. DOI: 10.1097/00005344-199206203-00010. View

12.

Hongo M, Takenaka H, Uchikawa S, Nakatsuka T, Watanabe N, Sekiguchi M . Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol. 1995; 75(4):246-50. DOI: 10.1016/0002-9149(95)80029-r. View

13.

Solal A, Jaeger P, Bouthier J, Juliard J, Dahan M, GOURGON R . Hemodynamic action of nicorandil in chronic congestive heart failure. Am J Cardiol. 1989; 63(21):44J-48J. DOI: 10.1016/0002-9149(89)90204-x. View

14.

Sakai K . Nicorandil: animal pharmacology. Am J Cardiol. 1989; 63(21):2J-10J. DOI: 10.1016/0002-9149(89)90198-7. View

15.

Miwa A, KANETA S, Motoki K, Jinno Y, Kasai H, Okada Y . Vasorelaxant mechanism of KRN2391 and nicorandil in porcine coronary arteries of different sizes. Br J Pharmacol. 1993; 109(3):632-6. PMC: 2175638. DOI: 10.1111/j.1476-5381.1993.tb13619.x. View

16.

Holzmann S . Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75). J Cardiovasc Pharmacol. 1983; 5(3):364-70. DOI: 10.1097/00005344-198305000-00004. View

17.

Yokota M, Horisawa T, Iwase M, Miyahara T, Yoshida J, Kamihara S . Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction. J Cardiovasc Pharmacol. 1987; 10 Suppl 8:S116-22. View

18.

Gross G, Auchampach J, Maruyama M, Warltier D, Pieper G . Cardioprotective effects of nicorandil. J Cardiovasc Pharmacol. 1992; 20 Suppl 3:S22-8. DOI: 10.1097/00005344-199206203-00006. View

19.

Arnold J, Kowey P, Wolf D, Jungbluth G, Hearron A, Luderer J . Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain. Int J Cardiol. 1994; 44(3):203-15. DOI: 10.1016/0167-5273(94)90284-4. View

20.

Suryapranata H, Serruys P, de Feyter P, Verdouw P, Hugenholtz P . Coronary vasodilatory action after a single dose of nicorandil. Am J Cardiol. 1988; 61(4):292-7. DOI: 10.1016/0002-9149(88)90933-2. View